1. Home
  2. VFC vs PTCT Comparison

VFC vs PTCT Comparison

Compare VFC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V.F. Corporation

VFC

V.F. Corporation

HOLD

Current Price

$17.10

Market Cap

6.6B

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$76.93

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VFC
PTCT
Founded
1899
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
6.5B
IPO Year
1994
2006

Fundamental Metrics

Financial Performance
Metric
VFC
PTCT
Price
$17.10
$76.93
Analyst Decision
Hold
Buy
Analyst Count
18
17
Target Price
$18.24
$80.65
AVG Volume (30 Days)
5.8M
1.5M
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
233.33
264.48
EPS
0.64
N/A
Revenue
$10,488,556,000.00
$264,734,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.06
$17.70
P/E Ratio
$25.83
N/A
Revenue Growth
N/A
36.19
52 Week Low
$11.11
$43.18
52 Week High
$22.27
$90.87

Technical Indicators

Market Signals
Indicator
VFC
PTCT
Relative Strength Index (RSI) 49.91 43.24
Support Level $15.81 $74.45
Resistance Level $16.94 $79.67
Average True Range (ATR) 0.55 3.27
MACD 0.03 -1.01
Stochastic Oscillator 65.88 4.47

Price Performance

Historical Comparison
VFC
PTCT

About VFC V.F. Corporation

VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and divestitures.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: